Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck ...

Immunocore Holdings' stock has dropped 60% as Kimmtrak faces market saturation, but its pipeline could offer potential. Find ...

The CR rate was consistent across subgroups including men and women, patients with and without papillary disease, and ...

Marc Dubrick and Grace Alexander claimed hard-fought victories Sunday morning in the 42nd St. Anthony's Triathlon along St.

Among research news last week, Gilead Sciences released positive new Phase III data on progression fee survival for its Trodelvy plus Keytruda in breast cancer. Roivant company Immunovant last week ...

Wall Street powered to its second-best weekly advance of 2025 on Friday, with the benchmark S&P 500 (SP500) jumping nearly 5%. For the week, the S&P advanced +4 ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...

Hera Women's Health ("Hera"), an Imperial Capital ("Imperial") portfolio company, is pleased to announce the appointment of Dr. Andy Wagner as the company's new Chief Executive Officer (CEO). Wagner ...

Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1/2 ...

With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. | With an ...

Antibody-drug conjugates continue to show benefits in breast cancer, plus the FDA has fast-tracked an innovative AI tool to help identify pancreatic tumors.